Has Reed Mitchell, MD received payments from drug or device companies?

Yes. Drug and device makers reported $356,632 in general payments to Reed Mitchell, MD across 284 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Reed Mitchell, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Reed Mitchell, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Reed Mitchell, MD

Hematology & Oncology · Richmond, VANPI 1225091267

Payments from drug & device makers

$356,632in general payments, 2019–2025

Across 284 payments — averaging $1255.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$231K
AstraZeneca$85K
F. Hoffmann-la Roche AG$18K
Astrazeneca UK Limited$12K
AbbVie$4K
Amgen$1K
plus $5K from 46 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	15	$231,019
AstraZeneca	32	$84,749
F. Hoffmann-la Roche AG	5	$17,621
Astrazeneca UK Limited	3	$12,266
AbbVie	12	$4,487
Amgen	5	$1,382
Novartis	36	$856
Boehringer Ingelheim International GmbH	3	$401
Pfizer	17	$362
Tersera Therapeutics LLC	11	$324
Ipsen Biopharmaceuticals, Inc	14	$302
Genentech USA, Inc.	10	$294
Merck	14	$261
Eisai Inc.	10	$212
Gilead(2 entities)	5	$186
Bayer	7	$154
Incyte Corporation	6	$117
EMD Serono, Inc.	5	$103
Daiichi Sankyo Inc.	4	$92
Sanofi	4	$87
Johnson & Johnson	4	$80
Seagen Inc.	3	$80
Karyopharm Therapeutics Inc.	3	$79
Lilly USA, LLC	4	$71
Regeneron Healthcare Solutions, Inc.	3	$65
Astellas Pharma US Inc	3	$64
Jazz Pharmaceuticals Inc.	3	$63
Puma Biotechnology, Inc.	3	$60
Boehringer Ingelheim	2	$57
Blueprint Medicines Corporation	3	$56
Takeda Pharmaceuticals U.S.A., Inc.	2	$56
Array Biopharma Inc	3	$51
Deciphera Pharmaceuticals Inc.	3	$49
Bristol Myers Squibb	3	$46
Pharmacyclics LLC, An Abbvie Company	3	$44
Progenics Pharmaceuticals, Inc.	2	$41
Alnylam Pharmaceuticals Inc.	1	$33
CTI Biopharma Corp.	1	$33
AVEO Pharmaceuticals, Inc.	2	$32
GSK	1	$31
Apellis Pharmaceuticals, Inc.	2	$30
Pharmaessentia USA Corporation	1	$30
Taiho Oncology, Inc.	1	$29
Geron Corporation	1	$26
Rigel Pharmaceuticals, Inc.	2	$26
Pharmacosmos Therapeutics Inc.	1	$25
Coherus Oncology, Inc.	1	$18
Agios Pharmaceuticals, Inc.	1	$18
Caris MPI, Inc.	1	$17
Morphosys, US Inc.	1	$16
ADC Therapeutics America, Inc.	1	$15
Sumitomo Pharma America, Inc.	1	$14

How this compares

$356,632 in reported general payments places this provider in the 80th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024

$2,798,692

Medicare patients

599

Services billed

142,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Richmond

Erin AlesiRichmond$1.7M
Sarah GordonRichmond$1M
Will VoelzkeRichmond$774K
James KhatcheressianRichmond$773K
Victor YazbeckRichmond$756K
William ClarkRichmond$685K
Elke FriedmanRichmond$571K
Joshua McFarlaneRichmond$390K
Jonathan BerkmanRichmond$360K
Hashim MannRichmond$331K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →